Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06613516 2025-12-24

CaptAin

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT04188119 2025-12-08

IMpALA

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT04756765 2025-08-17

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT05554211 2025-02-21

Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT05488444 2024-10-22

A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT06105008 2024-08-23

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT05212701 2024-04-30

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms, Fatigue

NCT03841747 2024-03-12

PELICAN

Phase 2 Withdrawn

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04102436 2024-03-12

Non-Viral TCR Gene Therapy

Phase 2 Withdrawn

BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Urogenital Neoplasms

NCT05689359 2024-03-08

Evaluation of Hydroxychloroquine to Prevent CIPN

Phase 2 Withdrawn

Breast

Breast Neoplasms, Peripheral Nervous System Diseases

NCT04199520 2024-03-04

Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT05703555 2024-02-28

INTRUSION

Phase 2 Withdrawn

BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Stomach Neoplasms

NCT05315687 2024-01-19

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT04265274 2023-10-06

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT05371860 2023-09-22

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

Phase 2 Withdrawn

Breast

Pathologic Complete Response, Breast Neoplasms

NCT04901299 2023-08-01

HER2-Signal

Phase 2 Withdrawn

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04675450 2023-06-08

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

Phase 2 Withdrawn

Breast

Breast Neoplasms, Peripheral Nervous System Diseases

NCT04190433 2023-05-24

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Phase 2 Withdrawn

BreastLymphoidOther hematologic neoplasmSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms

NCT05079360 2023-03-24

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT02067416 2023-02-02

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT05233696 2022-12-06

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Phase 2 Withdrawn

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04538833 2022-11-23

GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT05041972 2022-09-13

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Phase 2 Withdrawn

BreastGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05227131 2022-07-11

MARGARET

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT04351230 2022-05-26

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT05359874 2022-05-04

DoT-FMI

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT02850419 2022-04-07

EURO-DIGNITY

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT04856475 2022-03-02

NeraBrain

Phase 2 Withdrawn

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04038489 2021-11-22

Breast 51

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT03940248 2021-10-06

APBI

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT03872505 2021-08-25

PANDoRA

Phase 2 Withdrawn

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03863301 2021-02-26

ABLATIVE-2

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT03524261 2020-10-19

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT04220476 2020-09-21

CIMER

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT01818999 2020-08-20

Ixabepilone and SBRT For Metastatic Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT03393117 2020-07-22

Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT03065712 2020-05-12

Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT03637868 2020-05-06

ERIBRAIN

Phase 2 Withdrawn

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03323424 2020-01-30

IRAM

Phase 2 Withdrawn

BreastGastrointestinalHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT03532087 2020-01-18

PERIDENO

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT02853071 2019-11-18

BEST

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT01679743 2019-11-15

GRN1005 for Brain Metastases From Breast or Lung Cancer

Phase 2 Withdrawn

BreastThoracic

Breast Neoplasms, Lung Neoplasms

NCT03185871 2019-11-15

Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT02538432 2019-11-04

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

Phase 2 Withdrawn

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Disease Progression

NCT03794596 2019-07-22

IMpALA

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT00960544 2019-06-14

Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT03644589 2019-04-26

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03058939 2019-04-22

Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT01134497 2018-05-22

PLANET

Phase 2 Withdrawn

Breast

Breast Neoplasms

Clinical Trials

MK-5890-003

CaptAin

IMpALA

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage

A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

PELICAN

Non-Viral TCR Gene Therapy

Evaluation of Hydroxychloroquine to Prevent CIPN

Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients

INTRUSION

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

HER2-Signal

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

MARGARET

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

DoT-FMI

EURO-DIGNITY

NeraBrain

Breast 51

APBI

PANDoRA

ABLATIVE-2

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer

CIMER

Ixabepilone and SBRT For Metastatic Breast Cancer

Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction

Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET

ERIBRAIN

IRAM

PERIDENO

BEST

GRN1005 for Brain Metastases From Breast or Lung Cancer

Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

IMpALA

Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer

PLANET